Headlines Specialties Covid-19 Trending Feeds ASCO20 Videos

FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer

U.S. Food and Drug Administration - FDA approves frontline Keytruda in unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer.

Read the full article here